ES2539904T3 - Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas - Google Patents
Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas Download PDFInfo
- Publication number
- ES2539904T3 ES2539904T3 ES12167170.5T ES12167170T ES2539904T3 ES 2539904 T3 ES2539904 T3 ES 2539904T3 ES 12167170 T ES12167170 T ES 12167170T ES 2539904 T3 ES2539904 T3 ES 2539904T3
- Authority
- ES
- Spain
- Prior art keywords
- opioid
- antagonist
- dosage form
- opioid antagonist
- naltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición de antagonista opioide que comprende un antagonista opioide dispersado en una matriz obtenida por extrusión de masas fundidas, en la que la matriz comprende uno o más de un material hidrófobo farmacéuticamente aceptable y convierte el antagonista en sustancialmente no liberable cuando la forma de dosificación se administra intacta, de tal manera que la relación de la cantidad de antagonista liberada desde dicha forma de dosificación después de la manipulación indebida, con respecto a la cantidad de dicho antagonista liberada desde dicha forma de dosificación intacta es aproximadamente 4:1 ó mayor, basándose en la disolución in-vitro a 1 hora de dicha forma de dosificación en 900 ml de Fluido Gástrico Simulado usando un aparato USP Tipo II (de paletas) a 75 rpm y a 37 grados C.
Description
5
10
15
20
25
30
35
40
45
50
55
60 EP 2517710
E12167170
18-06-2015
[0051] La expresión “manipulación indebida” significa cualquier manipulación por medios mecánicos, térmicos y/o químicos que cambia las propiedades físicas de la forma de dosificación, por ejemplo, con el fin de liberar el agonista opioide para una liberación inmediata si el mismo se encuentra en forma de liberación sostenida, o para conseguir que el agonista opioide esté disponible para un uso inapropiado tal como su administración por una vía alternativa, por ejemplo, parenteralmente. La manipulación indebida puede ser, por ejemplo, por medio de machacadura, corte, trituración, masticación, disolución en un disolvente, calentamiento (por ejemplo, mayor que aproximadamente 45 ºC), o cualquier combinación de los mismos.
[0052] La expresión “que bloquea por lo menos parcialmente el efecto opioide” se define a efectos de la presente invención de modo que significa que el antagonista opioide bloquea por lo menos significativamente el efecto eufórico del agonista opioide, reduciendo de este modo el potencial de abuso del agonista opioide en la forma de dosificación.
[0053] En ciertas realizaciones preferidas de la presente invención, la forma sustancialmente no liberable del antagonista opioide comprende partículas de antagonista opioide en un recubrimiento que evita sustancialmente la liberación del antagonista. En realizaciones preferidas, el recubrimiento comprende uno o más de material hidrófobo farmacéuticamente aceptable. El recubrimiento es preferentemente impermeable al antagonista opioide contenido en el mismo y es insoluble en el sistema gastrointestinal, evitando sustancialmente de este modo la liberación del antagonista opioide cuando la forma de dosificación se administra oralmente según se desee.
[0054] Por consiguiente, cuando la forma de dosificación oral no se manipula indebidamente para comprometer la integridad del recubrimiento, el antagonista opioide contenido en la misma no se liberará sustancialmente durante su primera hora de tránsito a través del sistema gastrointestinal, y por lo tanto no estaría disponible para su absorción. En ciertas realizaciones preferidas de la presente invención, el material hidrófobo comprende un polímero de celulosa o un polímero acrílico que es insoluble en los fluidos gastrointestinales e impermeable al antagonista opioide.
[0055] El término “partículas” de antagonista opioide, tal como se usa en el presente documento, se refiere a gránulos, esferoides, perlas o pellets que comprenden el antagonista opioide. En ciertas realizaciones preferidas, las partículas de antagonista opioide tienen un diámetro de entre aproximadamente 0,2 y aproximadamente 2 mm, más preferentemente un diámetro de entre aproximadamente 0,5 y aproximadamente 2 mm.
[0056] En ciertas realizaciones de la presente invención, la forma de dosificación oral comprende además un antagonista opioide en una forma liberable y por lo tanto tiene la capacidad de ser liberado desde la forma de dosificación oral cuando se administra oralmente, siendo la relación del agonista opioide con respecto a la forma liberable del antagonista opioide tal que la forma de dosificación, cuando se administra oralmente, es analgésicamente eficaz. Por ejemplo, cuando el antagonista opioide se recubre con un recubrimiento que evita sustancialmente su liberación, y a continuación se mezcla con un agonista opioide y se prensa para obtener comprimidos, ciertas cantidades del recubrimiento se podrían agrietar, dejando así al descubierto el antagonista opioide para ser liberado tras la administración oral.
[0057] Preferentemente, el agonista opioide útil para la presente invención se puede seleccionar del grupo consistente en morfina, hidromorfona, hidrocodona, oxicodona, codeína, levorfanol, meperidina, metadona y mezclas de los mismos. Ejemplos preferidos del antagonista opioide útil para la presente invención incluyen naltrexona, naloxona, nalmefeno, ciclazacina, levalorfano, sales farmacéuticamente aceptables de los mismos y mezclas de los mismos.
[0058] En ciertas realizaciones de la presente invención, la relación del agonista opioide y el antagonista opioide, presente en una forma sustancialmente no liberable, está entre aproximadamente 1:1 y aproximadamente 50:1 en peso, preferentemente entre aproximadamente 1:1 y aproximadamente 20:1 en peso o entre 15:1 y aproximadamente 30:1. La relación en peso del agonista opioide con respecto al antagonista opioide, según se usa en la presente solicitud, se refiere al peso de los ingredientes activos. De este modo, por ejemplo, el peso del antagonista opioide excluye el peso del recubrimiento o matriz que convierte al antagonista opioide en sustancialmente no liberable, u otros posibles excipientes asociados a las partículas antagonistas. En ciertas realizaciones preferidas, la relación está entre aproximadamente 1:1 y aproximadamente 10:1 en peso. Puesto que el antagonista opioide está en una forma sustancialmente no liberable, la cantidad de dicho antagonista dentro de la forma de dosificación se puede hacer variar más ampliamente que las formas de dosificación combinadas de agonista/antagonista opioides en las que ambos están disponibles para la liberación al producirse la administración, en la medida en la que la formulación no depende del metabolismo diferencial o del aclaramiento hepático para un funcionamiento correcto. Por razones de seguridad, la cantidad del antagonista opioide presente en una forma sustancialmente no liberable se selecciona de manera que no sea perjudicial para humanos incluso si la misma se liberara completamente por manipulación indebida de la forma de dosificación.
[0059] En ciertas realizaciones preferidas de la presente invención, el agonista opioide comprende hidrocodona, oxicodona o sales farmacéuticamente aceptables de las mismas y el antagonista opioide, presente en una forma sustancialmente no liberable, comprende naloxona, naltrexona o sales farmacéuticamente aceptables de las mismas.
8
5
10
15
20
25
30
35
40
45
50
55
60 EP 2517710
E12167170
18-06-2015
ciclazacina, levalorfano, y mezclas de los mismos. En ciertas realizaciones preferidas, el antagonista opioide es naloxona o naltrexona. En ciertas realizaciones, la cantidad del antagonista opioide, presente en una forma sustancialmente no liberable, puede estar aproximadamente entre 10 ng y 275 mg.
[0095] La naloxona es un antagonista opioide que está prácticamente desprovisto de efectos agonistas. Dosis subcutáneas de hasta 12 mg de naloxona producen efectos subjetivos no discernibles, y 24 mg de naloxona provocan solamente una ligera somnolencia. Dosis pequeñas (entre 0,4 y 0,8 mg) de naloxona proporcionada intramuscular o intravenosamente en el ser humano evitan o invierten puntualmente los efectos de un agonista opioide de tipo morfina. Se ha publicado que un mg de naloxona intravenosamente bloquea completamente el efecto de 25 mg de heroína. Los efectos de la naloxona se observan casi inmediatamente después de la administración intravenosa. El fármaco se absorbe después de su administración oral, aunque se ha publicado que se metaboliza en una forma inactiva rápidamente en su primer paso a través del hígado de tal manera que se ha publicado que tiene una potencia significativamente menor que cuando se administra parenteralmente. Se ha publicado que la dosificación oral de más de 1 g se metaboliza casi completamente en menos de 24 horas. Se ha publicado que se absorbe el 25 % de naloxona administrada sublingualmente. Weinberg, et al., Sublingual Absorption of selected Opioid Analgesics, Clin Pharmacol Ther. (1988); 44:335-340.
[0096] Otros antagonistas opioides, por ejemplo, ciclazocina y naltrexona, que presentan ambas, sustituciones de ciclopropilmetilo en el nitrógeno, conservan mucha de su eficacia por la vía oral y sus duraciones de acción son mucho más prolongadas, aproximándose a 24 horas después de dosis orales.
[0097] En el tratamiento de pacientes que han sido previamente adictos a opioides, la naltrexona se ha usado en grandes dosis orales (por encima de 100 mg) para evitar efectos euforizantes de agonistas opioides. Se ha publicado que la naltrexona ejerce una acción de bloqueo fuerte preferencial contra sitios mu con respecto a delta. La naltrexona se conoce como un congénere sintético de la oximorfona sin propiedades agonistas opioides, y difiere en cuanto a estructura con respecto a la oximorfona en la sustitución del grupo metilo situado en el átomo de nitrógeno de la oximorfona por un grupo ciclopropilmetilo. La sal clorhidrato de naltrexona es soluble en agua hasta aproximadamente 100 mg/cc. Las propiedades farmacológicas y farmacocinéticas de la naltrexona se han evaluado en múltiples estudios animales y clínicos. Véase, por ejemplo, Gonzalez JP, et al. Naltrexone: A review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence. Drugs 1988; 35:192213, incorporada por la presente a título de referencia. Tras su administración oral, la naltrexona es absorbida rápidamente (en 1 hora) y presenta una biodisponibilidad oral comprendida entre el 5 y el 40 %. La unión a proteínas de la naltrexona es aproximadamente del 21 % y el volumen de distribución tras una administración de una sola dosis es 16,1 L/kg.
[0098] La naltrexona está disponible comercialmente en forma de comprimidos (Revia®, DuPont) para el tratamiento de la dependencia alcohólica y para el bloqueo de opioides administrados exógenamente. Véase, por ejemplo, Revia (comprimidos de clorhidrato de naltrexona). Physician’s Desk Reference 51ª ed., Montvale, NJ. “Medical Economics” 1997; 51:957-959. Una dosificación de 50 mg de Revia® bloquea los efectos farmacológicos de 25 mg de heroína administrada por IV durante hasta 24 horas.
[0099] Se sabe que cuando se administra conjuntamente con morfina, heroína u otros opioides de forma crónica, la naltrexona bloquea el desarrollo de dependencia física con respecto a opioides. Se cree que el método mediante el cual la naltrexona bloquea los efectos de la heroína es mediante unión competitiva en los receptores opioides. La naltrexona se ha usado para tratar la adicción a narcóticos mediante el bloqueo completo de los efectos de opioides. Se ha observado que el uso más satisfactorio de la naltrexona para una adicción a los narcóticos es con adictos a narcóticos que tienen un buen pronóstico, como parte de un programa integral ocupacional o de rehabilitación que conlleve un control de la conducta u otros métodos mejoradores del cumplimiento. Para el tratamiento de la dependencia de los narcóticos con naltrexona, es deseable que el paciente esté sin opioides durante por lo menos entre 7 y 10 días. La dosificación inicial de naltrexona con dichos fines ha sido típicamente de forma aproximada 25 mg, y si no se produce ningún signo de síndrome de abstinencia, la dosificación se puede aumentar a 50 mg por día. Se considera que una dosificación diaria de 50 mg produce un bloqueo clínico adecuado de las acciones de opioides administrados parenteralmente. La naltrexona se ha usado también para el tratamiento de alcoholismo como un complemento con métodos sociales y sicoterapéuticos.
[0100] En ciertas realizaciones de la presente invención, la relación del agonista opioide con respecto a la forma sustancialmente no liberable de un antagonista opioide en la forma de dosificación oral es tal que el efecto del agonista opioide se ve por lo menos parcialmente bloqueado cuando la forma de dosificación es masticada, machacada o disuelta en un disolvente y calentada, y se administra oral, intranasal, parenteral o sublingualmente. Puesto que la forma de dosificación oral de la presente invención, cuando se administra correctamente tal como se pretende, no liberaría sustancialmente el antagonista opioide, la cantidad de dicho antagonista se puede hacer variar más ampliamente que si el antagonista opioide está disponible para ser liberado al sistema gastrointestinal al producirse la administración oral. Por razones de seguridad, la cantidad del antagonista presente en una forma sustancialmente no liberable no debería ser perjudicial para seres humanos incluso si se liberara en su totalidad. La relación del agonista opioide particular con
13
5
10
15
20
25
30
35
40
45
50
55
60 EP 2517710
E12167170
18-06-2015
un aumento de peso de entre aproximadamente el 2 y aproximadamente el 25 % del sustrato de manera que se obtenga un perfil deseado de liberación sostenida. Se describen recubrimientos obtenidos a partir de dispersiones acuosas de forma detallada, por ejemplo, en las patentes U.S. n.º 5.273.760 y 5.286.493, cedidas al cesionario de la presente invención e incorporadas por la presente a título de referencia.
[0133] Otros ejemplos de formulaciones y recubrimientos de liberación sostenida que se pueden usar según la presente invención incluyen las patentes U.S. del cesionario n.º 5.324.351; 5.356.467 y 5.472.712, incorporadas por la presente a título de referencia en su totalidad.
Polímeros de alquilcelulosa
[0134] Los materiales y polímeros celulósicos, incluyendo alquilcelulosas, proporcionan materiales hidrófobos muy adecuados para el recubrimiento de las perlas según la invención. Simplemente a título de ejemplo, un polímero alquilcelulósico preferido es la etilcelulosa, aunque los expertos apreciarán que se pueden utilizar fácilmente otros polímeros de celulosa y/o alquilcelulosa, de forma individual o en cualquier combinación, como un todo o como parte de un recubrimiento hidrófobo según la invención.
[0135] Una dispersión acuosa comercialmente disponible de etilcelulosa es el Aquacoat® (FMC Corp., Philadelphia, Pennsylvania, U.S.A.). El Aquacoat® se prepara disolviendo la etilcelulosa en un disolvente orgánico inmiscible en agua y a continuación emulsificando el mismo en agua en presencia de un surfactante y un estabilizador. Después de la homogeneización para generar gotitas submicrónicas, el disolvente orgánico se evapora al vacío para formar un pseudolátex. El plastificante no se incorpora en el pseudolátex durante la fase de fabricación. De este modo, antes de usar el mismo como recubrimiento, es necesario mezclar íntimamente el Aquacoat® con un plastificante adecuado antes de su uso.
[0136] Otra dispersión acuosa de etilcelulosa está disponible comercialmente como Surelease® (Colorcon, Inc., West Point, Pennsylvania, U.S.A.). Este producto se prepara incorporando plastificante en la dispersión durante el proceso de fabricación. Se prepara una masa fundida en caliente de un polímero, un plastificante (sebacato de dibutilo), y un estabilizador (ácido oleico) en forma de una mezcla homogénea, la cual a continuación se diluye con una solución alcalina para obtener una dispersión acuosa que se puede aplicar directamente sobre sustratos.
Polímeros acrílicos
[0137] En otras realizaciones preferidas de la presente invención, el material hidrófobo que comprende el recubrimiento de liberación controlada es un polímero acrílico farmacéuticamente aceptable, que incluye, aunque sin limitarse a los mismos, copolímeros de ácido acrílico y ácido metacrílico, copolímeros de metacrilato de metilo, metacrilatos de etoxietilo, metacrilato de cianoetilo, poli(ácido acrílico), poli(ácido metacrílico), copolímero de alquilamida ácido metacrílico, poli(metacrilato de metilo), polimetacrilato, copolímero de poli(metacrilato de metilo), poliacrilamida, copolímero de metacrilato de aminoalquilo, poli(anhídrido de ácido metacrílico), y copolímeros de metacrilato de glicidilo.
[0138] En ciertas realizaciones preferidas, el polímero acrílico está compuesto por uno o más copolímeros de metacrilato y amonio. Los copolímeros de metacrilato y amonio son bien conocidos en la técnica, y se describen en NF XVII como copolímeros totalmente polimerizados de ésteres de ácido acrílico y metacrílico con un bajo contenido de grupos amónicos cuaternarios.
[0139] Para obtener un perfil de disolución deseable, puede que sea necesario incorporar dos o más copolímeros de metacrilato y amonio que tengan propiedades físicas diferentes, tales como relaciones molares diferentes de los grupos amónicos cuaternarios con respecto a los ésteres (met)acrílicos neutros.
[0140] Ciertos polímeros del tipo éster de ácido metacrílico son útiles para preparar recubrimientos dependientes del pH que se pueden usar según la presente invención. Por ejemplo, existe una familia de copolímeros sintetizados a partir de metacrilato de dietilaminoetilo y otros ésteres metacrílicos neutros, conocidos también como copolímero de ácido metacrílico o metacrilatos poliméricos, disponibles comercialmente como Eudragit® en Röhm Tech, Inc. Existen varios tipos diferentes de Eudragit®. Por ejemplo, Eudragit® E es un ejemplo de un copolímero de ácido metacrílico que se hincha y se disuelve en medios ácidos. Eudragit® L es un copolímero de ácido metacrílico que no se hincha con aproximadamente un pH < 5,7 y que es soluble con aproximadamente un pH > 6. Eudragit® S no se hincha con aproximadamente un pH < 6,5 y es soluble con aproximadamente un pH > 7. Eudragit® RL y Eudragit® RS son hinchables en agua, y la cantidad de agua absorbida por estos polímeros depende del pH, aunque las formas de dosificación recubiertas con Eudragit® RL y RS son independientes del pH.
[0141] En ciertas realizaciones preferidas, el recubrimiento acrílico comprende una mezcla de dos lacas de resina acrílica disponibles comercialmente en Rohm Pharma con los nombres comerciales Eudragit® RL30D y Eudragit® RS30D, respectivamente. Eudragit® RL30D y Eudragit® RS30D son copolímeros de ésteres acrílicos y metacrílicos con un bajo contenido de grupos amónicos cuaternarios, siendo la relación molar de los grupos amónicos con respecto a los
18
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18136900P | 2000-02-08 | 2000-02-08 | |
US181369P | 2000-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2539904T3 true ES2539904T3 (es) | 2015-07-07 |
Family
ID=22663996
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12167170.5T Expired - Lifetime ES2539904T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
ES10011790.2T Expired - Lifetime ES2539945T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
ES09006024T Expired - Lifetime ES2415407T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
ES01909086T Expired - Lifetime ES2326730T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas. |
ES10011789.4T Expired - Lifetime ES2540103T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10011790.2T Expired - Lifetime ES2539945T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
ES09006024T Expired - Lifetime ES2415407T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
ES01909086T Expired - Lifetime ES2326730T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas. |
ES10011789.4T Expired - Lifetime ES2540103T3 (es) | 2000-02-08 | 2001-02-08 | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
Country Status (35)
Country | Link |
---|---|
US (15) | US6696088B2 (es) |
EP (6) | EP2277521B1 (es) |
JP (10) | JP2003522144A (es) |
KR (2) | KR20020071032A (es) |
CN (3) | CN101703777B (es) |
AP (1) | AP1665A (es) |
AT (1) | ATE431145T1 (es) |
AU (2) | AU776666B2 (es) |
BG (1) | BG65828B1 (es) |
BR (2) | BR0108379A (es) |
CA (1) | CA2400567C (es) |
CY (2) | CY1109270T1 (es) |
CZ (1) | CZ299991B6 (es) |
DE (1) | DE60138706D1 (es) |
DK (5) | DK2283842T3 (es) |
EA (1) | EA004876B1 (es) |
EE (1) | EE05171B1 (es) |
ES (5) | ES2539904T3 (es) |
GE (1) | GEP20053614B (es) |
HK (3) | HK1051487A1 (es) |
HU (2) | HU229705B1 (es) |
IL (5) | IL151057A0 (es) |
ME (1) | MEP48308A (es) |
MX (2) | MXPA02007690A (es) |
NO (2) | NO20023729L (es) |
NZ (1) | NZ520554A (es) |
OA (1) | OA12215A (es) |
PL (1) | PL210845B1 (es) |
PT (6) | PT1299104E (es) |
RS (1) | RS50407B (es) |
SI (5) | SI2283842T1 (es) |
SK (1) | SK287107B6 (es) |
TW (1) | TWI292317B (es) |
UA (1) | UA79069C2 (es) |
WO (2) | WO2001058451A1 (es) |
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1685839T1 (sl) | 1997-12-22 | 2013-08-30 | Euro-Celtique S.A. | Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
TR200001828T2 (tr) * | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
NZ520554A (en) | 2000-02-08 | 2005-08-26 | Euro Celtique S | Tamper-resistant oral opioid agonist formulations |
JP2004512354A (ja) | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク,エス.エイ. | ヒドロコドン放出制御製剤 |
US7858118B2 (en) * | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
AU2002303718B2 (en) * | 2001-05-11 | 2008-02-28 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
CN1525851A (zh) * | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
WO2003002100A1 (en) * | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
EP1404332A1 (en) * | 2001-07-06 | 2004-04-07 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone related applications |
CN1268338C (zh) * | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
DK1416842T3 (da) * | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US20030157168A1 (en) * | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
DE60232417D1 (de) | 2001-08-06 | 2009-07-02 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030049317A1 (en) * | 2001-08-30 | 2003-03-13 | Lindsay David R. | Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
MXPA04003597A (es) | 2001-10-18 | 2004-07-30 | Nektar Therapeutics Al Corp | Conjugados polimericos de antagonistas opiaceos. |
EP1450824A4 (en) * | 2001-11-02 | 2005-09-28 | Elan Corp Plc | PHARMACEUTICAL COMPOSITION |
US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
CA2477004C (en) * | 2002-02-22 | 2011-05-10 | Thomas Piccariello | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
CA2478558C (en) * | 2002-03-14 | 2012-09-11 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0206505D0 (en) * | 2002-03-19 | 2002-05-01 | Euro Celtique Sa | Pharmaceutical combination |
DE60327807D1 (de) * | 2002-03-26 | 2009-07-09 | Euro Celtique Sa | Gelbeschichtete zusammensetzungen mit verzögerter freisetzung |
KR20040098050A (ko) * | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
DE60325709D1 (de) | 2002-04-09 | 2009-02-26 | Flamel Tech Sa | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
CA2480824A1 (fr) * | 2002-04-09 | 2003-10-16 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline |
WO2003090729A1 (en) | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
WO2004004693A1 (en) * | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP1535615A4 (en) * | 2002-07-11 | 2010-03-31 | Taiho Pharmaceutical Co Ltd | COMPOSITION FOR THE NASAL ABSORPTION |
US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
DE10237056A1 (de) * | 2002-08-09 | 2004-03-04 | Grünenthal GmbH | Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin |
EP1894562B1 (en) * | 2002-08-15 | 2010-12-15 | Euro-Celtique S.A. | Pharmaceutical compositions comprising an opioid antagonist |
PT1551372T (pt) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Subunidade de sequestração e composições e métodos relacionados |
CA2498798A1 (en) * | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sustained-release opioid formulations and methods of use |
EP1551402A4 (en) * | 2002-09-23 | 2009-05-27 | Verion Inc | PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE |
DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
WO2004041328A2 (en) | 2002-10-31 | 2004-05-21 | Euro-Celtique S.A. | Pharmaceutical identification |
US20040110781A1 (en) * | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
DE10305137A1 (de) * | 2003-02-07 | 2004-08-26 | Novosis Ag | Transdermale therapeutische Abgabesysteme mit einem Butenolid |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
JP5501553B2 (ja) * | 2003-04-21 | 2014-05-21 | ユーロ−セルティーク エス.エイ. | 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程 |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
EA009623B1 (ru) * | 2003-04-30 | 2008-02-28 | Пэдью Фарма Л.П. | Устойчивая к манипуляциям дозировочная форма для трансдермального введения |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
ES2407143T3 (es) * | 2003-08-06 | 2013-06-11 | Grünenthal GmbH | Forma de dosificación protegida contra un posible abuso |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
ES2344350T3 (es) * | 2003-09-25 | 2010-08-25 | Euro-Celtique S.A. | Combinaciones farmaceuticas de hidrocodona y naltrexona. |
EP2298303A1 (en) * | 2003-09-25 | 2011-03-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
US20050245557A1 (en) * | 2003-10-15 | 2005-11-03 | Pain Therapeutics, Inc. | Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain |
AU2004281153A1 (en) * | 2003-10-15 | 2005-04-28 | Pain Therapeutics, Inc. | Treatment of arthritic conditions, chronic inflammation or pain |
AU2004286852A1 (en) | 2003-10-30 | 2005-05-19 | Alza Corporation | Transdermal analgesic systems having reduced abuse potential |
DK1691892T3 (da) * | 2003-12-09 | 2007-06-25 | Euro Celtique Sa | Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme |
US8883204B2 (en) | 2003-12-09 | 2014-11-11 | Purdue Pharma L.P. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
ME02661B (me) * | 2004-02-23 | 2017-06-20 | Euro Celtique Sa | Opioidni transdermalni preparat otporan na zloupotrebu |
TWI483944B (zh) * | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | 含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
ATE419836T1 (de) | 2004-03-30 | 2009-01-15 | Euro Celtique Sa | Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
ES2653568T3 (es) * | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
CA2576386A1 (en) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
US7226619B1 (en) | 2004-09-07 | 2007-06-05 | Pharmorx Inc. | Material for controlling diversion of medications |
US7827983B2 (en) * | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
JP5704789B2 (ja) * | 2005-01-28 | 2015-04-22 | ユーロ−セルティーク エス.エイ. | 耐アルコール性剤形 |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1879557A1 (en) * | 2005-05-13 | 2008-01-23 | Alpharma, Inc. | Morphine sulfate formulations |
EP1895985A1 (en) * | 2005-05-13 | 2008-03-12 | Alpharma, Inc. | Morphine sulphate formulations |
US8632800B2 (en) | 2005-05-13 | 2014-01-21 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
ES2277743B2 (es) * | 2005-06-02 | 2008-12-16 | Universidade De Santiago De Compostela | Nanoparticulas que comprenden quitosano y ciclodextrina. |
WO2006133733A1 (en) * | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
WO2007016563A2 (en) * | 2005-08-01 | 2007-02-08 | Alpharma Inc. | Alcohol resistant pharmaceutical formulations |
JP5164840B2 (ja) | 2005-08-02 | 2013-03-21 | ソル − ゲル テクノロジーズ リミテッド | 水不溶性成分の金属酸化物被覆 |
WO2008134071A1 (en) * | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US8329744B2 (en) * | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
WO2007070632A2 (en) * | 2005-12-13 | 2007-06-21 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
EP1810714A1 (de) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution |
EP1810678A1 (de) † | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
SG169334A1 (en) * | 2006-01-21 | 2011-03-30 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US7939567B2 (en) * | 2006-02-24 | 2011-05-10 | Blue Blood Biotech Corp. | Dextromethorphan-based method for treating acne |
FR2898056B1 (fr) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | Comprimes resistant a l'ecrasement destines a eviter le detournement illicite |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
CN101453993A (zh) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
JP2009535409A (ja) * | 2006-05-03 | 2009-10-01 | コーワ ファーマシューティカルズ アメリカ,インコーポレイティド | 即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬 |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8158156B2 (en) | 2006-06-19 | 2012-04-17 | Alpharma Pharmaceuticals, Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
AU2011205222B2 (en) * | 2006-07-21 | 2014-02-27 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
AU2007275033A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
CN103550136B (zh) * | 2006-07-21 | 2016-04-13 | 生物递送科学国际公司 | 吸收增强的经粘膜递送装置 |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US8187636B2 (en) * | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
AU2007322269A1 (en) * | 2006-10-11 | 2008-05-29 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
PT2101740E (pt) | 2006-12-04 | 2013-12-23 | Orexo Ab | Nova composição farmacêutica não susceptível de abuso que compreende opióides |
EA200970724A1 (ru) | 2007-02-01 | 2010-02-26 | Сол-Джел Текнолоджиз Лтд. | Композиции для местного применения, содержащие пероксид и ретиноид |
GB2447014A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
CA2678367C (en) | 2007-03-02 | 2014-07-08 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
EP2187873B1 (en) | 2007-08-13 | 2018-07-25 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
PL2197429T3 (pl) * | 2007-09-03 | 2016-09-30 | Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków | |
AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
WO2009079518A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals. Llc | Pharmaceutical composition |
WO2009079521A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
JP5651818B2 (ja) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | 誤用を防止するための放出制御製剤 |
EP2224915A4 (en) * | 2007-12-17 | 2014-01-22 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITIONS |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AU2015200313B2 (en) * | 2007-12-17 | 2016-12-01 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
EP2259780A2 (en) | 2008-02-28 | 2010-12-15 | Syntropharma Limited | Pharmaceutical composition comprising naltrexone |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
CA2730211C (en) * | 2008-07-07 | 2016-11-08 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
NZ592437A (en) | 2008-10-30 | 2013-03-28 | Gruenenthal Chemie | A dosage form comprising tapentadol and an opioid antagonist |
ES2414856T3 (es) * | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Formulaciones de fármaco narcótico con potencial de adicción disminuido |
AU2009327312A1 (en) | 2008-12-16 | 2011-08-04 | Labopharm Europe Limited | Misuse preventative, controlled release formulation |
AU2009332963B2 (en) | 2008-12-31 | 2015-02-05 | Upsher-Smith Laboratories, Llc | Opioid-containing oral pharmaceutical compositions and methods |
EP3045043B1 (en) * | 2009-02-26 | 2020-04-29 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
EP2405915B1 (en) | 2009-03-10 | 2018-10-24 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
EP2421515A2 (de) * | 2009-04-22 | 2012-02-29 | Lars Holger Hermann | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
US9023390B2 (en) | 2009-09-17 | 2015-05-05 | Upsher-Smith Laboratories, Inc. | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
WO2011112956A1 (en) * | 2010-03-12 | 2011-09-15 | Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services | Agonist/antagonist compositions and methods of use |
AR083150A1 (es) * | 2010-05-10 | 2013-02-06 | Euro Celtique Sa | Composiciones farmaceuticas que comprenden hidromorfona y naloxona |
BR112012028656A2 (pt) * | 2010-05-10 | 2016-08-09 | Euro Celtique Sa | combinação de grânulos carregados ativos com ativos adicionais |
CA2798884C (en) | 2010-05-10 | 2016-09-13 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
WO2011143120A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholres i stant metoprolol - containing extended - release oral dosage forms |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
DE102010048883A1 (de) | 2010-10-19 | 2012-04-19 | Lars Holger Hermann | Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
JP2012087101A (ja) * | 2010-10-21 | 2012-05-10 | Holger Hermann Lars | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 |
MY166034A (en) | 2010-12-22 | 2018-05-21 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
JP5638151B2 (ja) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | 不正加工抵抗性の(tamperresistant)固形経口剤形 |
TWI554271B (zh) * | 2010-12-28 | 2016-10-21 | 歐 賽提克股份有限公司 | 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合 |
CN102068697B (zh) * | 2010-12-30 | 2013-10-16 | 宜昌人福药业有限责任公司 | 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物 |
RU2013136350A (ru) | 2011-02-02 | 2015-03-27 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист |
CA2827273A1 (en) | 2011-02-17 | 2012-08-23 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
EP2726065A4 (en) * | 2011-06-30 | 2014-11-26 | Neos Therapeutics Lp | MISS-BROKEN MEDICINAL PRODUCTS |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
ES2660116T3 (es) | 2011-08-18 | 2018-03-20 | Biodelivery Sciences International, Inc. | Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina |
DK2706986T3 (en) | 2011-09-19 | 2015-06-01 | Orexo Ab | NEW ADDICTION PREVENTING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OPIOID ADDICTION |
CN104010630A (zh) * | 2011-12-09 | 2014-08-27 | 普渡制药公司 | 包含聚(ε-己内酯)和聚氧乙烯的药物剂型 |
JP6289378B2 (ja) | 2011-12-12 | 2018-03-07 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ブプレノルフィンを含む経皮送達システム |
SG10202012743WA (en) * | 2011-12-21 | 2021-01-28 | Biodelivery Sciences Int Inc | Transmucosal drug delivery devices for use in chronic pain relief |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9687445B2 (en) * | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
CN104302280A (zh) | 2012-04-17 | 2015-01-21 | 普渡制药公司 | 用于治疗阿片样物质所致不良药效学响应的系统和方法 |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US9427403B2 (en) | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US8802658B2 (en) | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
HUE049859T2 (hu) | 2012-06-06 | 2020-10-28 | Nalpropion Pharmaceuticals Llc | Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra |
PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
US9687465B2 (en) | 2012-11-27 | 2017-06-27 | Sol-Gel Technologies Ltd. | Compositions for the treatment of rosacea |
KR101659983B1 (ko) * | 2012-12-31 | 2016-09-26 | 주식회사 삼양바이오팜 | 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제 |
US9149533B2 (en) | 2013-02-05 | 2015-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9517208B2 (en) | 2013-03-15 | 2016-12-13 | Purdue Pharma L.P. | Abuse-deterrent dosage forms |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US20140275038A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
ITTO20130284A1 (it) * | 2013-04-09 | 2014-10-10 | Fond Istituto Italiano Di Tecnologia | Procedimento per la produzione di microparticelle polimeriche sagomate |
MX371432B (es) * | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
MA38698B1 (fr) | 2013-06-04 | 2017-10-31 | Lts Lohmann Therapie Systeme Ag | Système d'administration transdermique |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
NZ716267A (en) | 2013-07-23 | 2017-05-26 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
MX2016005477A (es) | 2013-10-31 | 2016-08-03 | Cima Labs Inc | Formas de dosificacion disuasivas del abuso. |
DE112014005175T5 (de) | 2013-11-13 | 2016-07-21 | Euro-Celtique S.A. | Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
ES2631504B1 (es) | 2014-03-14 | 2018-11-28 | Opiant Pharmaceuticals, Inc. | Medicamentos de administración nasal y métodos para su uso |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
US10493027B2 (en) | 2014-08-07 | 2019-12-03 | Mucodel Pharma Llc | Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery |
EP3177270A4 (en) * | 2014-08-07 | 2018-01-24 | Mucodel Pharma LLC | Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
JP6696994B2 (ja) | 2014-12-08 | 2020-05-20 | クレシオ・バイオサイエンシズ・リミテッド | 即放性乱用抑止性顆粒剤形 |
EP3229785A2 (de) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxon-monopräparat und mehrschichttablette |
FR3032353B1 (fr) | 2015-02-06 | 2017-03-10 | Jacques Seguin | Composition pharmaceutique et dispositif pour le traitement de la douleur |
CN107889459A (zh) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
WO2017039778A1 (en) * | 2015-08-31 | 2017-03-09 | Regents Of The University Of Minnesota | Opioid receptor modulators and use thereof |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
KR20180050400A (ko) * | 2015-09-09 | 2018-05-14 | 미셀 테크놀로지즈, 인코포레이티드 | 미셀 기술의 생물약학 적용 |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
GB201520390D0 (en) * | 2015-11-19 | 2016-01-06 | Euro Celtique Sa | Composition |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US10532385B2 (en) | 2016-06-29 | 2020-01-14 | Disposerx, Inc. | Disposal of medicaments |
WO2018012627A1 (ja) * | 2016-07-15 | 2018-01-18 | シャープ株式会社 | 送風装置および空気調和機 |
WO2018208241A1 (en) * | 2017-05-10 | 2018-11-15 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Formulation and optimization of controlled release tablets of morphine sulphate |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US11690840B2 (en) * | 2017-10-09 | 2023-07-04 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
CA3075292A1 (en) * | 2017-10-20 | 2019-04-25 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
CN109232748B (zh) * | 2018-09-26 | 2019-06-11 | 哈尔滨工业大学 | 多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用 |
US20220105085A1 (en) * | 2019-01-31 | 2022-04-07 | Relmada Therapeutics, Inc. | Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE |
WO2021005501A1 (en) * | 2019-07-10 | 2021-01-14 | Intas Pharmaceuticals Ltd. | Naltrexone formulation |
IT201900013473A1 (it) * | 2019-07-31 | 2021-01-31 | Vetagro Int S R L | Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale |
EP3936112A1 (en) * | 2020-07-07 | 2022-01-12 | Occlugel | Hydrophilic degradable microspheres for delivering buprenorphine |
US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
AU2023211592A1 (en) * | 2022-01-26 | 2024-08-01 | Aardvark Therapeutics, Inc. | Liquid resin extended-release oral naltrexone formulation for treating autism-related disorders |
Family Cites Families (230)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US316889A (en) | 1885-04-28 | Soil pulverizer and leveler | ||
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4587118A (en) | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
WO1983003197A1 (en) | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
DE3434946A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Diarylacetylene, ihre herstellung und verwendung |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CA1267092A (en) | 1985-02-25 | 1990-03-27 | Martin D. Hynes | Analgesic composition containing codeine |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
DE3687575T2 (de) | 1985-09-06 | 1993-07-01 | Baker Norton Pharma | Verwendung von 6-methylen-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphin. |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
EP0219243A2 (en) | 1985-10-11 | 1987-04-22 | Advanced Micro Devices, Inc. | Process of manufacturing a bipolar transistor |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ATE107857T1 (de) | 1986-06-10 | 1994-07-15 | Euro Celtique Sa | Zusammensetzung mit kontrollierter freisetzung von dihydrocodein. |
US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
DE3636075A1 (de) * | 1986-10-23 | 1988-04-28 | Merck Patent Gmbh | Kosmetische zubereitungen |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4831781A (en) * | 1987-11-02 | 1989-05-23 | Dayton Extruded Plastics, Inc. | Window assembly of rigid plastics material |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
JPH01279895A (ja) * | 1988-01-20 | 1989-11-10 | Baker Cummins Pharmaceut Inc | オピオイド拮抗剤のグルクロン酸誘導体 |
DE3812567A1 (de) | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (en) * | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5260331A (en) | 1989-01-02 | 1993-11-09 | John Wyeth & Brother Limited | Composition for treating depression with (S- or O-heteroaryl)alkyl amines |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
FR2663818B1 (fr) | 1990-06-29 | 1993-07-09 | Rhone Poulenc Nutrition Animale | Procede de preparation de granules de principes actifs par extrusion. |
FR2669336B1 (fr) | 1990-11-20 | 1993-01-22 | Adir | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
ZA922180B (en) * | 1991-03-29 | 1993-09-27 | Lilly Co Eli | Piperidine derivatives |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
KR100243956B1 (ko) | 1991-09-06 | 2000-03-02 | 랄프 알. 팔로 | 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물 |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5226331A (en) | 1991-10-03 | 1993-07-13 | General Electric Company | Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
GB9203689D0 (en) | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
EP0647137B1 (en) | 1992-06-22 | 2008-08-13 | The Regents Of The University Of California | Glycine receptor antagonists and the use thereof |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
JP2563100Y2 (ja) | 1992-08-05 | 1998-02-18 | 日本精工株式会社 | シートベルト用リトラクター |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
WO1994006426A1 (en) | 1992-09-21 | 1994-03-31 | Qin Bo Yi | Methods for identifying and using low/non-addictive opioid analgesics |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (de) | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
US5411965A (en) | 1993-08-23 | 1995-05-02 | Arizona Board Of Regents | Use of delta opioid receptor antagonists to treat cocaine abuse |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP1442745A1 (en) * | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5411745A (en) | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
DE69525847T2 (de) | 1994-09-19 | 2002-09-05 | Dupont Pharmaceuticals Co., Wilmington | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
EP1609477B1 (en) | 1994-12-12 | 2011-11-09 | Omeros Corporation | Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
CA2195119C (en) * | 1995-06-09 | 2001-09-11 | Mark Chasin | Formulations and methods for providing prolonged local anesthesia |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
WO1997020819A1 (en) * | 1995-12-06 | 1997-06-12 | Eli Lilly And Company | Composition for treating pain |
EP0914097B1 (en) * | 1996-03-12 | 2002-01-16 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
CA2220768A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
DE19654468C1 (de) | 1996-12-27 | 1998-01-22 | Lohmann Therapie Syst Lts | Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung |
DE29719704U1 (de) | 1997-02-14 | 1998-01-22 | Gödecke AG, 10587 Berlin | Stabile Zubereitungen von Naloxonhydrochlorid |
WO1998035679A1 (de) | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6120806A (en) | 1997-06-25 | 2000-09-19 | Whitmire; David R. | Oral formulations for controlled release of alcohol deterrents |
CA2270975C (en) | 1997-07-02 | 2003-04-01 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
EP0913152B1 (de) | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
SI1685839T1 (sl) * | 1997-12-22 | 2013-08-30 | Euro-Celtique S.A. | Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista |
TR200001828T2 (tr) * | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
US6248691B1 (en) | 1998-02-10 | 2001-06-19 | Corning Incorporated | Method of making mesoporous carbon |
KR20010043820A (ko) * | 1998-05-27 | 2001-05-25 | 유로셀띠끄 소시에떼 아노님 | 치밀하게 컴팩트된 고체약물스톡을 포함하는 약물전달시스템 |
FR2787715B1 (fr) | 1998-12-23 | 2002-05-10 | Synthelabo | Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables |
DE19859636A1 (de) | 1998-12-23 | 2000-06-29 | Hexal Ag | Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff |
US6312949B1 (en) | 1999-03-26 | 2001-11-06 | The Salk Institute For Biological Studies | Regulation of tyrosine hydroxylase expression |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
EP1225897B1 (en) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
IL149600A0 (en) | 1999-11-29 | 2002-11-10 | Adolor Corp | Novel methods and compositions involving opioids and antagonists thereof |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
NZ520554A (en) | 2000-02-08 | 2005-08-26 | Euro Celtique S | Tamper-resistant oral opioid agonist formulations |
DE60119696T2 (de) | 2000-03-15 | 2007-01-25 | Wolfgang Ross Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
AU5945801A (en) | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Opoid antagonist compositions and dosage forms |
JP2003535833A (ja) | 2000-06-09 | 2003-12-02 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | ナルブフィンとオピオイドアンタゴニストを使用した疼痛の処置法 |
CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
AU2002303718B2 (en) | 2001-05-11 | 2008-02-28 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US6555080B1 (en) * | 2001-07-13 | 2003-04-29 | Chevron U.S.A. Inc. | Using zeolite SSZ-57 for reduction of oxides of nitrogen in a gas stream |
DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
DE60232417D1 (de) | 2001-08-06 | 2009-07-02 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
CA2478558C (en) | 2002-03-14 | 2012-09-11 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
DE60327807D1 (de) | 2002-03-26 | 2009-07-09 | Euro Celtique Sa | Gelbeschichtete zusammensetzungen mit verzögerter freisetzung |
KR20040098050A (ko) | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
EP1894562B1 (en) | 2002-08-15 | 2010-12-15 | Euro-Celtique S.A. | Pharmaceutical compositions comprising an opioid antagonist |
CA2498798A1 (en) | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sustained-release opioid formulations and methods of use |
PT1551372T (pt) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Subunidade de sequestração e composições e métodos relacionados |
US20050191244A1 (en) | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
WO2004071423A2 (en) | 2003-02-05 | 2004-08-26 | Euro-Celtique S.A. | Methods of administering opioid antagonists and compositions thereof |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US20080020028A1 (en) | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
ES2344350T3 (es) | 2003-09-25 | 2010-08-25 | Euro-Celtique S.A. | Combinaciones farmaceuticas de hidrocodona y naltrexona. |
US20050245557A1 (en) | 2003-10-15 | 2005-11-03 | Pain Therapeutics, Inc. | Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain |
DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
AU2004296821B2 (en) | 2003-12-05 | 2011-05-12 | Carefusion 303, Inc. | Patient-controlled analgesia with patient monitoring system |
US20050256072A1 (en) * | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
US8158156B2 (en) | 2006-06-19 | 2012-04-17 | Alpharma Pharmaceuticals, Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
AU2007322269A1 (en) | 2006-10-11 | 2008-05-29 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
WO2009032270A2 (en) | 2007-09-04 | 2009-03-12 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
US20100151014A1 (en) | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
EP2224915A4 (en) | 2007-12-17 | 2014-01-22 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITIONS |
WO2009079518A1 (en) | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals. Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
WO2009079521A1 (en) | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2011322147A1 (en) | 2010-10-26 | 2013-04-18 | Alpharma Pharmaceuticals, Llc | Formulations and methods for attenuating respiratory depression induced by opioid overdose |
RU2013136350A (ru) | 2011-02-02 | 2015-03-27 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист |
-
2001
- 2001-02-08 NZ NZ520554A patent/NZ520554A/en not_active IP Right Cessation
- 2001-02-08 ME MEP-483/08A patent/MEP48308A/xx unknown
- 2001-02-08 PT PT01909086T patent/PT1299104E/pt unknown
- 2001-02-08 IL IL15105701A patent/IL151057A0/xx active IP Right Grant
- 2001-02-08 EP EP10011789.4A patent/EP2277521B1/en not_active Revoked
- 2001-02-08 CZ CZ20022706A patent/CZ299991B6/cs not_active IP Right Cessation
- 2001-02-08 ES ES12167170.5T patent/ES2539904T3/es not_active Expired - Lifetime
- 2001-02-08 ES ES10011790.2T patent/ES2539945T3/es not_active Expired - Lifetime
- 2001-02-08 PT PT90060245T patent/PT2092936E/pt unknown
- 2001-02-08 AU AU36876/01A patent/AU776666B2/en not_active Expired
- 2001-02-08 AU AU36877/01A patent/AU776904B2/en not_active Expired
- 2001-02-08 SI SI200131043T patent/SI2283842T1/sl unknown
- 2001-02-08 ES ES09006024T patent/ES2415407T3/es not_active Expired - Lifetime
- 2001-02-08 CN CN2009102080743A patent/CN101703777B/zh not_active Expired - Lifetime
- 2001-02-08 DK DK10011790.2T patent/DK2283842T3/en active
- 2001-02-08 KR KR1020027010121A patent/KR20020071032A/ko not_active Application Discontinuation
- 2001-02-08 OA OA1200200241A patent/OA12215A/en unknown
- 2001-02-08 PT PT121671705T patent/PT2517710E/pt unknown
- 2001-02-08 KR KR1020027010211A patent/KR100552038B1/ko active IP Right Grant
- 2001-02-08 MX MXPA02007690A patent/MXPA02007690A/es unknown
- 2001-02-08 MX MXPA02007686A patent/MXPA02007686A/es active IP Right Grant
- 2001-02-08 PT PT100117902T patent/PT2283842E/pt unknown
- 2001-02-08 BR BR0108379-1A patent/BR0108379A/pt not_active Application Discontinuation
- 2001-02-08 EE EEP200200437A patent/EE05171B1/xx unknown
- 2001-02-08 CA CA002400567A patent/CA2400567C/en not_active Expired - Lifetime
- 2001-02-08 SI SI200131021T patent/SI2092936T1/sl unknown
- 2001-02-08 BR BRPI0108380-5 patent/BRPI0108380B8/pt not_active IP Right Cessation
- 2001-02-08 PT PT01909087T patent/PT1255547E/pt unknown
- 2001-02-08 HU HU0204229A patent/HU229705B1/hu unknown
- 2001-02-08 SK SK1134-2002A patent/SK287107B6/sk not_active IP Right Cessation
- 2001-02-08 CN CNB018065694A patent/CN100563656C/zh not_active Expired - Lifetime
- 2001-02-08 EP EP10011790.2A patent/EP2283842B1/en not_active Expired - Lifetime
- 2001-02-08 EP EP15160341.2A patent/EP3130338A1/en not_active Withdrawn
- 2001-02-08 DK DK10011789.4T patent/DK2277521T3/en active
- 2001-02-08 EA EA200200840A patent/EA004876B1/ru not_active IP Right Cessation
- 2001-02-08 DK DK01909086T patent/DK1299104T3/da active
- 2001-02-08 DK DK09006024.5T patent/DK2092936T3/da active
- 2001-02-08 EP EP12167170.5A patent/EP2517710B1/en not_active Expired - Lifetime
- 2001-02-08 DE DE60138706T patent/DE60138706D1/de not_active Expired - Lifetime
- 2001-02-08 EP EP01909086A patent/EP1299104B1/en not_active Expired - Lifetime
- 2001-02-08 AP APAP/P/2002/002617A patent/AP1665A/en active
- 2001-02-08 JP JP2001557557A patent/JP2003522144A/ja active Pending
- 2001-02-08 CN CN01807725A patent/CN1423559A/zh active Pending
- 2001-02-08 SI SI200131041T patent/SI2517710T1/sl unknown
- 2001-02-08 HU HU0204163A patent/HUP0204163A2/hu unknown
- 2001-02-08 ES ES01909086T patent/ES2326730T3/es not_active Expired - Lifetime
- 2001-02-08 SI SI200130928T patent/SI1299104T1/sl unknown
- 2001-02-08 GE GE4855A patent/GEP20053614B/en unknown
- 2001-02-08 PT PT100117894T patent/PT2277521E/pt unknown
- 2001-02-08 DK DK12167170.5T patent/DK2517710T3/en active
- 2001-02-08 RS YUP-589/02A patent/RS50407B/sr unknown
- 2001-02-08 ES ES10011789.4T patent/ES2540103T3/es not_active Expired - Lifetime
- 2001-02-08 WO PCT/US2001/004346 patent/WO2001058451A1/en active Search and Examination
- 2001-02-08 EP EP09006024A patent/EP2092936B1/en not_active Expired - Lifetime
- 2001-02-08 JP JP2001557561A patent/JP2003522146A/ja not_active Withdrawn
- 2001-02-08 SI SI200131042T patent/SI2277521T1/sl unknown
- 2001-02-08 WO PCT/US2001/004347 patent/WO2001058447A1/en active Search and Examination
- 2001-02-08 PL PL385885A patent/PL210845B1/pl unknown
- 2001-02-08 US US09/781,081 patent/US6696088B2/en not_active Expired - Lifetime
- 2001-02-08 AT AT01909086T patent/ATE431145T1/de active
- 2001-04-17 TW TW090102735A patent/TWI292317B/zh not_active IP Right Cessation
- 2001-08-02 UA UA2002097179A patent/UA79069C2/uk unknown
-
2002
- 2002-08-01 IL IL151057A patent/IL151057A/en unknown
- 2002-08-07 NO NO20023729A patent/NO20023729L/no not_active Application Discontinuation
- 2002-08-07 NO NO20023728A patent/NO324717B1/no not_active IP Right Cessation
- 2002-08-08 BG BG106986A patent/BG65828B1/bg unknown
-
2003
- 2003-03-28 HK HK03102267.9A patent/HK1051487A1/zh unknown
- 2003-09-29 HK HK03107027.9A patent/HK1056822A1/xx not_active IP Right Cessation
- 2003-10-21 US US10/689,866 patent/US7842311B2/en not_active Expired - Lifetime
- 2003-11-04 US US10/700,906 patent/US7682632B2/en active Active
- 2003-11-04 US US10/700,893 patent/US7718192B2/en active Active
- 2003-11-04 US US10/700,861 patent/US7842309B2/en not_active Expired - Lifetime
- 2003-11-04 US US10/701,041 patent/US7658939B2/en not_active Expired - Lifetime
-
2007
- 2007-02-15 IL IL181356A patent/IL181356A/en active IP Right Grant
- 2007-10-10 JP JP2007264445A patent/JP2008019280A/ja active Pending
-
2009
- 2009-02-04 JP JP2009023739A patent/JP5351538B2/ja not_active Expired - Lifetime
- 2009-08-04 CY CY20091100824T patent/CY1109270T1/el unknown
-
2010
- 2010-02-24 HK HK10101944.3A patent/HK1135907A1/xx not_active IP Right Cessation
- 2010-03-25 IL IL204761A patent/IL204761A/en active IP Right Grant
- 2010-10-21 US US12/909,614 patent/US8236351B2/en not_active Expired - Fee Related
-
2011
- 2011-09-13 IL IL215132A patent/IL215132A0/en unknown
-
2012
- 2012-02-16 JP JP2012032017A patent/JP5676504B2/ja not_active Expired - Lifetime
- 2012-06-20 JP JP2012138857A patent/JP2012176993A/ja active Pending
- 2012-07-09 US US13/544,333 patent/US8357399B2/en not_active Expired - Lifetime
- 2012-12-18 US US13/718,879 patent/US8586088B2/en not_active Expired - Fee Related
-
2013
- 2013-06-18 CY CY20131100491T patent/CY1114063T1/el unknown
- 2013-10-04 US US14/045,961 patent/US8936812B2/en not_active Expired - Fee Related
-
2014
- 2014-05-01 JP JP2014094376A patent/JP2014169306A/ja active Pending
- 2014-10-31 JP JP2014222704A patent/JP6063427B2/ja not_active Expired - Lifetime
- 2014-12-10 US US14/565,904 patent/US9456989B2/en not_active Expired - Lifetime
-
2015
- 2015-03-23 US US14/665,670 patent/US9278073B2/en not_active Expired - Fee Related
-
2016
- 2016-08-24 US US15/245,338 patent/US9801828B2/en not_active Expired - Fee Related
- 2016-10-04 JP JP2016196329A patent/JP2016222730A/ja active Pending
- 2016-10-25 JP JP2016208382A patent/JP6403742B2/ja not_active Expired - Lifetime
-
2017
- 2017-09-26 US US15/715,425 patent/US10350173B2/en not_active Expired - Fee Related
-
2019
- 2019-06-05 US US16/432,719 patent/US10588865B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2539904T3 (es) | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas | |
JP5566102B2 (ja) | 医薬組成物 | |
ES2677769T3 (es) | Subunidad secuestrante y composiciones y procedimientos relacionados | |
ES2415876T3 (es) | Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos | |
ES2625092T3 (es) | Formas de dosificación orales resistentes a la adicción y método de uso de las mismas | |
US8465774B2 (en) | Sequestered antagonist formulations | |
KR100893895B1 (ko) | 치료제와 반작용제를 함유하는 경구 투여제 | |
JPH07206679A (ja) | 持効性経口投与オピオイド製剤 | |
NZ530971A (en) | Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists | |
JP2010506833A (ja) | 医薬組成物 | |
WO2005007135A1 (en) | Pharmaceutical compositions | |
BR112013019431A2 (pt) | composição farmacêutica compreendendo agonista opioide e antagonista sequestrado |